Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use ...
Pharmacy strike plan: what would 'collective action' mean for you and what services are affected?
The historic action, which was voted for in a ballot by the National Pharmacy Association (NPA), saw 99% of pharmacy owners ...